Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy.

ABSTRACT: During oncogenesis, tumor cells present specific carbohydrate chains that are new targets for cancer immunotherapy. Whereas these tumor-associated carbohydrates (TACA) can be targeted with antibodies and vaccination approaches, TACA including sialic acid-containing glycans are able to inhibit anticancer immune responses by engagement of immune receptors on leukocytes. A family of immune-modulating receptors are sialic acid-binding Siglec receptors that have been recently described to inhibit antitumor activity mediated by myeloid cells, natural killer cells and T cells. Other TACA-binding receptors including selectins have been linked to cancer progression. Recent studies have shown that glycan-lectin interactions can be targeted to improve cancer immunotherapy. For example, interactions b

SUBMITTER: Rodrigues Mantuano N 

PROVIDER: S-EPMC7537339 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature